CharacterisatiON of carDiac funCTion in Intensive Care Unit Survivors of Sepsis.
NCT ID: NCT05633290
Last Updated: 2023-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
69 participants
OBSERVATIONAL
2023-03-01
2024-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Indicators of Inflammation and Coagulation in Sepsis
NCT01128283
Multiple Biomarkers in ICU Sepsis Patients
NCT03802136
Pneumonia in the Intensive Care Unit (ICU) Setting
NCT02685930
SIRS and Bacterial Sepsis Discrimination by Biomarkers in ICU
NCT01378169
Mechanisms of Precise Immune Cell Phenotyping and Prognostic Prediction in Severe Infection
NCT07332793
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Investigators will collect cardiac and inflammatory biomarkers from participants at the point of discharge from ICU. Following discharge from hospital, cardiac magnetic resonance (CMR) scans of the heart will be undertaken in participants 6-10 weeks post-discharge from hospital to examine for evidence of inflammation in the heart. Further blood samples will also be collected to look for evidence of inflammation and heart muscle injury at this point in addition to patient reported outcomes measures using validated questionnaires.
Participants will be identified with their direct clinical team in ICU and are nearing or at the point of discharge from ICU. If eligible for the study, they will be approached by researchers and provided them with an information sheet and written consent form. Participants will be given up to 24hrs to decide if they wish to take part in research and if so, they will sign the consent form. Participants are free to withdraw from the study at any time, without any reason given, and this would not affect the standard of care they receive.
This is an observational cohort study. If willing to take part, participants will receive the normal follow-up that would be undertaken following discharge from ICU. In addition, researchers will collect a sample of blood from participants at the time of discharge from ICU and again at 6 -10 weeks post discharge. A Cardiac Magnetic Resonance (CMR) scan will be undertaken 6-10 weeks follow up.
Researchers will assess the patient's day-to-day function and quality of life by asking them to complete validated questionnaires. These questionnaires should take five to ten minutes to complete and help will be available if required. Participants will complete these questionnaires at the follow-up visit 6-10 weeks following discharge from hospital with the help of the researchers conducting the study
The first blood sample will be collected following discharge from ICU whilst the patient is still in hospital. Further blood samples will be collected 6-10 weeks following discharge from hospital. Blood samples for patients undergoing CMR will be taken when they attend for scan. Blood sampling for patients who do not undergo CMR imaging will attend for a separate follow-up visit for collection of samples.
Patients are normally invited to attend ICU follow-up via the InS:PIRE service at approximately 6-10 weeks post-discharge. Where possible researchers will combine blood sample analysis with routine follow-up visits in clinic to which participants would normally be invited. If they are not able to attend follow-up and are not attending for CMR scan, then researchers will invite them to the research facility within the local sites for collection of samples.
Samples will be stored in NHS Biorepository and analyzed within the British Heart Foundation Laboratory at the University of Glasgow.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ICU Survivors of Sepsis
ICU survivors of sepsis who would routinely attend ICU follow-up.
CMR
CMR Imaging 6-10 weeks post hospital discharge.
hs-troponin
Biomarker of myocardial injury
NT-pro BNP
Biomarker for heart failure
CRP
Acute phase inflammatory marker
IL1-B
Inflammatory biomarker
IL-6
Inflammatory Biomarker
IL-10
Inflammatory Biomarker
TNF-alpha
Inflammatory Biomarker
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CMR
CMR Imaging 6-10 weeks post hospital discharge.
hs-troponin
Biomarker of myocardial injury
NT-pro BNP
Biomarker for heart failure
CRP
Acute phase inflammatory marker
IL1-B
Inflammatory biomarker
IL-6
Inflammatory Biomarker
IL-10
Inflammatory Biomarker
TNF-alpha
Inflammatory Biomarker
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age \> 18 years.
3. ICU admission with sepsis (According to The Third International Consensus Definitions for Sepsis and Septic Shock \[Sepsis-3\])17
4. Ability to comply with study procedures
Exclusion Criteria
2. Pregnancy.
3. Ongoing participation in any investigational research that may undermine the scientific basis of the study.
4. Contraindications to magnetic resonance imaging:
i. Cardiac pacemaker, artificial heart valve, neurostimulator, cochlear implant ii. Aneurysm clips iii. Metal injuries to the eye iv. Loose metal in any part of the body v. Severe claustrophobia
5. Known Coronary Artery Disease
6. Previous Myocardial Infarction
7. Chronic Heart Failure prior to ICU admission
8. Patient receiving immune modulating drug or biologic therapy either long term or during acute admission
9. Patient considered by the clinical team to be very unlikely to survive to hospital discharge
10. Hospital Admission because of Covid-19
11. Patients undergoing treatment for malignancy with systemic anti-cancer therapies.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NHS Ayrshire and Arran
OTHER
Golden Jubilee National Hospital
OTHER_GOV
University of Glasgow
OTHER
NHS Greater Glasgow and Clyde
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Glasgow Royal Infirmary
Glasgow, , United Kingdom
University Hospital Crosshouse
Kilmarnock, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Garrity K, Docherty C, Mangion K, Woodward R, Shaw M, Roditi G, Shelley B, Quasim T, McCall P, McPeake J. Characterizing Cardiac Function in ICU Survivors of Sepsis: A Pilot Study Protocol. CHEST Crit Care. 2024 Mar;2(1):100050. doi: 10.1016/j.chstcc.2024.100050.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GN22CA029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.